Jefferies is maintaining their Buy rating on shares of Amylin Pharmaceuticals (NASDAQ: AMLN) as the company recently announced that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE